[Apoptosis of human hepatocellular carcinoma HepG-2 cells upon inhibition of STAT3 by 5,2’,4’-trihydroxy-6,7,5’-trimethoxy flavone nanoparticle].

药学学报 Pub Date : 2016-12-01

Bin Xiao, Xuan Zhang, Mei-lan Zhang, Xue-wu Zhang

引用次数: 0

Abstract

This study was designed to investigate the mechanism of 5,2’,4’-trihydroxy-6,7,5’-trimethoxy flavone nanoparticle (TTF1-NP) in the induction of apoptosis of human hepatocellular carcinoma HepG-2 cells. MTT assay, immunocytochemical staining and flow cytometry with Annexin V-FITC/PI were used to demonstrate inhibition of proliferation of HepG-2 cells and cell apoptosis. The inhibition was studied in a dose- and time-dependent manner. Western blot results showed that TTF1-NP down-regulated the signals of survivin, p-STAT3 and STAT3, but up-regulated the expression level of cleaved caspase-3. Taken together, our results showed that TTF1-NP induced HepG-2 cell apoptosis through inhibition of the STAT3 expression.

本刊更多论文

[5,2 '，4 ' -三羟基-6,7,5 ' -三甲氧基黄酮纳米颗粒抑制STAT3对人肝癌HepG-2细胞凋亡的影响]。

本实验旨在探讨5,2 '，4 ' -三羟基-6,7,5 ' -三甲氧基黄酮纳米颗粒(TTF1-NP)诱导人肝癌HepG-2细胞凋亡的机制。MTT法、免疫细胞化学染色和Annexin V-FITC/PI流式细胞术检测HepG-2细胞增殖和细胞凋亡的抑制作用。以剂量和时间依赖性的方式研究了抑制作用。Western blot结果显示，TTF1-NP下调survivin、p-STAT3和STAT3信号，上调cleaved caspase-3的表达水平。综上所述，我们的研究结果表明TTF1-NP通过抑制STAT3的表达诱导HepG-2细胞凋亡。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

药学学报 Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)

CiteScore

1.20

自引率

0.00%

发文量

期刊介绍： Acta Pharmaceutica Sinica B (APSB) is a bimonthly English peer-reviewed online journal in ScienceDirect, which publishes significant original research articles, communications and high quality reviews of recent advances. APSB encourages submissions from all areas of pharmaceutical sciences, including pharmacology, pharmaceutics, medicinal chemistry, natural products, pharmacognosy, pharmaceutical analysis and pharmacokinetics. APSB is a part of the series Acta Pharmaceutica Sinica, which was founded in 1953. The journal is co-published by Elsevier B.V., in association with the Institute of MateriaMedica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association.